Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
L01EK01 Axitinib
D03218 Axitinib (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors
Axitinib
D03218 Axitinib (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D03218 Axitinib (JAN/USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03203 VEGFR inhibitor
D03218 Axitinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D03218 Axitinib
DG02925 CYP3A5 substrate
D03218 Axitinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
VEGFR family
VEGFR1 (FLT1)
D03218 Axitinib (JAN/USAN) <JP/US>
VEGFR2 (KDR)
D03218 Axitinib (JAN/USAN) <JP/US>
VEGFR3 (FLT4)
D03218 Axitinib (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03218
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03218
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03218
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03218
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03218